How Autologous Cell Therapy Works: The Mechanism in Plain Language | ALIV

Understanding how Autologous Cell Therapy works is important not just for intellectual curiosity but for setting realistic expectations and making an informed clinical decision. Patients who understand the mechanism are better positioned to understand why results take time, why protocols differ by condition, and why ALIV is precise about who is and is not an appropriate candidate. This article explains the ACT process from cell harvest through to the body's regenerative response — in clinical but accessible language.

Step One: Cell Harvest

The biological material for ACT at ALIV is harvested from the patient's own body. Depending on the protocol and the clinical indication, the source material may be bone marrow (typically harvested from the posterior iliac crest of the pelvis under local anaesthesia) or adipose tissue (harvested from the abdomen or flank via a small lipoaspiration procedure under local anaesthesia). Both sources contain populations of adult mesenchymal cells — progenitor cells with the capacity to support tissue repair — alongside a rich milieu of growth factors, cytokines, and signalling molecules that form the biologically active component of the ACT preparation.

The harvest procedure is performed in ALIV's clinical suite under sterile conditions. The volumes obtained are typically small — a few millilitres of bone marrow aspirate or adipose tissue — and the procedure is generally well-tolerated under local anaesthesia. The harvest site is the source of any procedural discomfort; the administration site is typically treated separately. Post-harvest, the material is transferred immediately to ALIV's on-site processing environment.

Step Two: Processing and Concentration

The harvested material is processed using validated laboratory protocols to isolate, concentrate, and prepare the therapeutically active cell populations and growth factors. This processing — involving centrifugation, filtration, and quality assessment steps — typically takes two to four hours. The goal is to produce a concentrated preparation with a defined content of the relevant cell populations and growth factors, at a quality and concentration level that exceeds what would naturally be present in the harvested tissue at the target site.

Growth factors concentrated in ACT preparations typically include: PDGF (Platelet-Derived Growth Factor — stimulates cell proliferation and tissue repair); TGF-β (Transforming Growth Factor-beta — modulates inflammation and promotes matrix formation); IGF-1 (Insulin-Like Growth Factor-1 — supports cell survival and muscle and nerve tissue repair); VEGF (Vascular Endothelial Growth Factor — stimulates new blood vessel formation essential for tissue repair); and HGF (Hepatocyte Growth Factor — supports liver, kidney, and epithelial tissue regeneration). The specific profile of growth factors varies between bone marrow and adipose source material and is partly what determines which source is selected for which condition. See: growth factors in ACT explained.

Step Three: Administration and Paracrine Signalling

The processed ACT preparation is administered by targeted injection into the affected tissue (intra-articular for joint conditions, intrathecal or intravenous for neurological conditions, hepatic portal for liver conditions, depending on the protocol) or systemically via intravenous infusion where systemic anti-inflammatory and regenerative effect is the primary goal.

Once administered, the therapeutic action operates primarily through paracrine signalling — the cells and growth factors in the ACT preparation communicate with surrounding cells and the local tissue environment through chemical signals, without necessarily integrating into the tissue themselves. These signals shift the local microenvironment: reducing chronic inflammatory cytokines (IL-1β, TNF-α, IL-6) that are driving tissue degradation; stimulating the patient's own progenitor cell populations to upregulate repair activity; promoting new blood vessel formation to improve oxygen and nutrient delivery to damaged tissue; and modulating the immune response in ways that support repair rather than chronic destruction. This is what is meant by calling ACT a regenerative and paracrine therapy rather than a cell replacement therapy. See the full clinical picture: what is ACT.

How long does it take for the body to respond to ACT?

The paracrine signalling begins immediately after administration, but the downstream tissue changes take weeks to months to produce clinically observable improvement. Initial responses — reduced inflammatory burden, improved energy levels, some reduction in pain — may be noticeable within two to six weeks. More substantive functional improvements (better joint mobility, improved neurological function, stabilised metabolic markers) typically develop over three to six months. Maximum benefit from a single ACT course is often seen at six to twelve months post-administration. This timeline reflects the biology of tissue repair, not a delay in the therapy's effectiveness.

Does ACT work differently for different conditions?

Yes — the mechanism emphasis varies by condition. For joint conditions (osteoarthritis, RA), the primary therapeutic goal is anti-inflammatory paracrine modulation and stimulation of cartilage matrix repair. For neurological conditions, the goal involves neurotrophic factor delivery (supporting neuronal survival and neuroplasticity) and neuroinflammation reduction. For liver disease, HGF-rich preparations support hepatocyte regeneration and fibrosis reduction. This condition-specific mechanism is why ALIV uses different source materials and different administration routes for different indications — a single universal protocol would be mechanistically sub-optimal for most conditions.

Is the ACT preparation stable after processing?

ACT preparations at ALIV are prepared fresh for immediate same-day administration — they are not stored, frozen, or banked for later use. The biological activity of the growth factor and cell components is best preserved in fresh preparations administered promptly after processing. This same-day protocol is part of ALIV's quality standard and is one reason the procedure involves a full clinical day at the facility from harvest through administration.

Can my body reject its own cells processed in the lab?

No — autologous rejection is immunologically impossible. Your immune system identifies self from non-self through HLA (Human Leukocyte Antigen) surface markers on cells. Cells that are yours, regardless of how they have been processed, retain your HLA signature. Your immune system does not mount a rejection response against them. This is the fundamental autologous safety advantage that distinguishes ACT from any therapy involving donor-derived cells, manufactured biologics, or foreign substances.